Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Despite the similarities there are some differences
2022-08-03

Despite the similarities, there are some differences between the augmentation by hypoxia and that by thymoquinone. While in porcine coronary arteries they both depend on calcium sensitization mediated by ROCK12, 32, 33, L-type calcium channels are involved only in thymoquinone-induced augmentation.
-
However although lactic acid suppresses the activation of ef
2022-08-02

However, although lactic L-Phenylephrine mg suppresses the activation of effector , rendering them unable to buffer intracellular acidity [32], other T cell subpopulations such as regulatory T cells (Tregs) exhibit metabolic adaptations in low-glucose, high-lactate environments. In particular, Treg
-
The timing and growth of follicles
2022-08-02

The timing and growth of follicles relative to follicle deviation was assessed in 49 cows (Fig. 4) that had NFWE following treatment onset and that had not already established dominance. Because day of deviation did not differ due to treatment, day of estrous cycle, or replicate, data are presented
-
FPG had no consistent activity in
2022-08-02

FPG-2 had no consistent activity in reducing G→T transversions. Gao and Murphy [2] earlier reported that FPG-2 had a limited amount of activity in vitro on depurinated, UV-treated, and methylene-blue-treated DNA (but not on 8-oxo-G-containing oligonucleotides). FPG-2 contains the N-terminal domain a
-
PBI is an agonist of GPR and acts as
2022-08-02

PBI-4050 is an agonist of GPR40 and acts as an antagonist or inverse agonist of GPR84. It cannot be excluded that other targets besides GPR40 and GPR84 could be implicated in the mechanism of action of PBI-4050 and could be explored in future studies. However, the present study, and in particular th
-
Ac-DEVD-AFC In the present study we characterized
2022-08-02

In the present study, we characterized the expression of glucose transporters in the developing and adult mouse lens and showed that GLUT1 is the primary transporter expressed in the lens epithelium. We found that mice with a homozygous deletion of Slc2a1 from the lens epithelium developed cataracts
-
Compound was obtained as a yellow
2022-08-02

Compound was obtained as a yellow crystal (acetone). And the molecular formula of was established as CHO on the basis of a quasi-molecular ion at / 331.0799 [M+H] (calcd. for 331.0818) in its HR-ESI-MS. Compound showed H and C NMR similar to those of ARCA Cy3 EGFP mRNA . However, The H NMR spectrum
-
GKRP binds to the inactive super open conformation of GCK
2022-08-02

GKRP binds to the inactive, super-open conformation of GCK, acting as a competitive inhibitor of glucose association with the enzyme (Fig. 3) [45]. Upon formation of the inhibitory complex with GKRP, GCK is sequestered into the hepatocyte nucleus [48]. The detailed mechanism by which GKRP mediates t
-
In conclusion we have shown that AKR D regulates
2022-08-02

In conclusion, we have shown that AKR1D1 regulates glucocorticoid availability and GR activation and therefore represents a key pre-receptor regulator of hormonal action in human liver. However, there are additional questions that need to be addressed including dissecting the broader role of AKR1D1
-
uPAR another newly discovered ligand has implicated FPRL
2022-08-02

uPAR, another newly discovered ligand, has implicated FPRL1 as a potential link between the fibrinolytic cascade and inflammation. uPA is a serine protease best known for its ability to regulate fibrinolysis and for its importance in tissue remodeling and tumor invasion [49]. However, uPA also induc
-
JTC-801 synthesis A breakthrough in the understanding of the
2022-08-02

A breakthrough in the understanding of the unique properties of GPX4-downregulation-induced cell death was accomplished when Seiler et al. in 2008 demonstrated the role of 12/15-lipoxygenase (12/15-LOX), a polyunsaturated fatty JTC-801 synthesis metabolizing enzyme [92], in the execution of GPX4-kno
-
br Conclusion br Acknowledgements This
2022-08-02

Conclusion Acknowledgements This work was supported by R01 HL127386 (Niklason) and 1R01 HL128406-01A1 (Dardik), and by an unrestricted research gift from Humacyte Inc. KLL was supported by F30HL143880. KLL and EQ were supported by T32 GM007205. LEN is a founder and shareholder in Humacyte, Inc
-
In addition to FAK P MAPK
2022-08-02

In addition to FAK, P-38 MAPK (38 kDa polypeptide) serves as cross-talk effector for signal transduction, enabling this factor to play a vital role in numerous biological processes (Cuenda and Rousseau, 2007). Pharmacologically modulation of P-38 has shown to be an effective approach in the orientat
-
Following the discovery of diketo compounds S and L as
2022-08-02

Following the discovery of β-diketo compounds S-1360 [31] and L-731988 [32] as anti-HIV integrase inhibitors, a group of researchers discovered a potent GX-674 receptor based derivative (1) as the inhibitor of HIV integrase functioning at the 3′-processing and strand transfer steps of HIV integrase.
-
Several named antagonist ligands have
2022-08-01

Several named antagonist ligands have figured noticeably in preclinical studies, with proved clear ability to release neurotransmitters and having efficacy in preclinical animal models. Consequently, this has encouraged ongoing research on improved agents with potency, selectivity, and better drug-l
16101 records 408/1074 page Previous Next First page 上5页 406407408409410 下5页 Last page